URSO FORTE (ursodiol) by AbbVie is ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. First approved in 1997.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
URSO FORTE (ursodiol) is an oral bile acid replacement therapy approved in 1997 for cholestatic liver diseases. It works by replacing toxic endogenous bile acids with ursodiol, a naturally occurring hydrophilic bile acid, while providing cytoprotection and immunomodulatory effects to damaged hepatocytes and cholangiocytes. The drug treats patients with primary biliary cirrhosis and primary sclerosing cholangitis.
Product approaching loss of exclusivity with modest Part D spending of $392K (304 claims in 2023), indicating a niche indication with limited commercial expansion potential and likely smaller team structure.
Ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. Oral administration of ursodiol increases this fraction in a dose related manner, to become the major biliary acid, replacing/displacing toxic…
Bile Acid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Ursodiol in Huntington's Disease
Ursodiol Tablets 500 mg Under Fasting Conditions
Ursodiol 500 mg Tablets Under Fed Conditions
Worked on URSO FORTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moURSO FORTE represents a niche, mature specialty pharma opportunity with stable but limited commercial potential. Career roles focus on defending market position and managing reimbursement rather than driving growth, making it suitable for experienced professionals seeking stable specialty positions rather than high-growth career trajectories.